Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Publication Type:
Journal ArticleSource:
Journal of the National Cancer Institute, Volume 101, Issue 6, p.374-83 (2009)Keywords:
2009, Aged, Aged, 80 and over, Center-Authored Paper, Early Detection of Cancer, Europe, Humans, Incidence, Male, Mass Screening, Middle Aged, Models, Statistical, Models, Theoretical, Netherlands, Prostate-Specific Antigen, Prostatic Neoplasms, Public Health Sciences Division, Risk Assessment, Risk Factors, SEER Program, Sensitivity and Specificity, Shared Resources, Time Factors, Tumor Markers, Biological, United StatesAbstract:
The time by which prostate-specific antigen (PSA) screening advances prostate cancer diagnosis, called the lead time, has been reported by several studies, but results have varied widely, with mean lead times ranging from 3 to 12 years. A quantity that is closely linked with the lead time is the overdiagnosis frequency, which is the fraction of screen-detected cancers that would not have been diagnosed in the absence of screening. Reported overdiagnosis estimates have also been variable, ranging from 25% to greater than 80% of screen-detected cancers.
Doing Business with Arnold Library
Weintraub Building, B1-010
(206) 667-4314
library@fredhutch.org
More About Arnold Library
Quick Links
- ILLiad/ILL Form
- Journals List
- Ovid - Medline
- Web of Science
- Pubmed
- Libguides
- Library Catalog
- Researcher Profiles
- Library Affiliations & Memberships
- Fred Hutch Papers (Intranet)